BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 01, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

PharmAthene, Bristol-Myers preclinical data

Valortim enhanced the killing of Bacillus anthracis by human dendritic cells in vitro. The human mAb targeting anthrax protective antigen (PA) also enhanced

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >